Preliminary experience of the use of a gonadotrophin-releasing hormone antagonist in ovulation induction/in-vitro fertilization prior to cancer treatment

被引:44
作者
Anderson, RA
Kinniburgh, D
Baird, DT
机构
[1] Univ Edinburgh, MRC, Reprod Biol Unit, Edinburgh EH3 9ET, Midlothian, Scotland
[2] Univ Edinburgh, Dept Obstet & Gynaecol, Ctr Reprod Biol, Edinburgh EH3 9ET, Midlothian, Scotland
关键词
cancer; GnRH antagonist; IVF; ovulation induction;
D O I
10.1093/humrep/14.10.2665
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Therapeutic regimens for the treatment of malignant disease may compromise future fertility. One approach to circumvent this is the cryopreservation of embryos created before treatment for the malignancy. Conventional regimens using gonadotrophin-releasing hormone (GnRH) agonists are time consuming, requiring pituitary down-regulation before gonadotrophin administration, thus the duration of treatment is similar to 20-30 days. GnRH antagonists, however, do not cause an initial stimulation of gonadotrophin secretion and can thus be administered during the later stages of follicular maturation to prevent premature luteinization and ovulation, The duration of ovulation induction/in-vitro fertilization (IVF) treatment is thus reduced, In this study, case histories are reported of six women with newly diagnosed malignancies who requested ovulation induction/IVF prior to chemotherapy or surgery in which we have used the GnRH antagonist Cetrorelix, Gonadotrophin administration was started in the early follicular phase, and Cetrorelix (0.25 mg s.c. daily) was added from day 6 of treatment. Subsequent to human chorionic gonadotrophin (HCG) administration oocytes were recovered and successful fertilization and embryo cryopreservation was achieved in all cases. The median duration of treatment was 12 days (range 8-13, including induction of luteolysis in two patients). These results illustrate the potential use and advantages of a GnRH antagonist in ovulation induction/IVF when the need for immediate initiation of treatment and its duration are critical factors.
引用
收藏
页码:2665 / 2668
页数:4
相关论文
共 21 条
[1]  
Albano C, 1996, HUM REPROD, V11, P2114
[2]   SUCCESSFUL PREGNANCY AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOID-LEUKEMIA [J].
ATKINSON, HG ;
APPERLEY, JF ;
DAWSON, K ;
GOLDMAN, JM ;
WINSTON, RML .
LANCET, 1994, 344 (8916) :199-199
[3]  
Bahadur G, 1996, HUM REPROD, V11, P2573
[4]   Blastocyst development and birth after in-vitro maturation of human primary oocytes, intracytoplasmic sperm injection and assisted hatching [J].
Barnes, FL ;
Crombie, A ;
Gardner, DK ;
Kausche, A ;
LachamKaplan, O ;
Suikkari, AM ;
Tiglias, J ;
Wood, C ;
Trounson, AO .
HUMAN REPRODUCTION, 1995, 10 (12) :3243-3247
[5]   Prevention of gonadal damage during cytotoxic therapy [J].
Blumenfeld, Z ;
Haim, N .
ANNALS OF MEDICINE, 1997, 29 (03) :199-206
[6]   SUPPRESSION OF THE ENDOGENOUS LUTEINIZING-HORMONE SURGE BY THE GONADOTROPIN-RELEASING-HORMONE ANTAGONIST CETRORELIX DURING OVARIAN STIMULATION [J].
DIEDRICH, K ;
DIEDRICH, C ;
SANTOS, E ;
ZOLL, C ;
ALHASANI, S ;
REISSMANN, T ;
KREBS, D ;
KLINGMULLER, D .
HUMAN REPRODUCTION, 1994, 9 (05) :788-791
[7]   Development in vitro of mouse oocytes from primordial follicles [J].
Eppig, JJ ;
OBrien, MJ .
BIOLOGY OF REPRODUCTION, 1996, 54 (01) :197-207
[8]   Hormone profiles under ovarian stimulation with human menopausal gonadotropin (hMG) and concomitant administration of the gonadotropin releasing hormone (GnRH)-antagonist cetrorelix at different dosages [J].
Felberbaum, R ;
Reissmann, T ;
Kupker, W ;
AlHasani, S ;
Bauer, O ;
Schill, T ;
Zoll, C ;
Diedrich, C ;
Diedrich, K .
JOURNAL OF ASSISTED REPRODUCTION AND GENETICS, 1996, 13 (03) :216-222
[9]   Role of different GnRH agonist regimens in pituitary suppression and the outcome of controlled ovarian hyperstimulation [J].
Filicori, M ;
Cognigni, GE ;
Arnone, R ;
Carbone, F ;
Falbo, A ;
Tabarelli, C ;
Ciampaglia, W ;
Casadio, P ;
Spettoli, D ;
Pecorari, R .
HUMAN REPRODUCTION, 1996, 11 :123-132
[10]   CONTROL OF THE PREOVULATORY LUTEINIZING-HORMONE SURGE BY GONADOTROPIN-RELEASING-HORMONE ANTAGONISTS - PROSPECTS FOR CLINICAL-APPLICATION [J].
FRASER, HM ;
BOUCHARD, P .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 1994, 5 (02) :87-93